Chardan Capital Raises Earnings Estimates for CervoMed

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Chardan Capital increased their FY2025 earnings per share estimates for CervoMed in a research note issued on Tuesday, May 13th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($2.57) per share for the year, up from their prior estimate of ($2.68). Chardan Capital has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Chardan Capital also issued estimates for CervoMed’s FY2026 earnings at ($1.09) EPS.

Several other equities research analysts also recently commented on the company. Jones Trading upgraded CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Thursday, March 13th. Canaccord Genuity Group upped their target price on shares of CervoMed from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. Roth Mkm raised their price target on shares of CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of CervoMed in a report on Tuesday, May 13th. Finally, Brookline Capital Management upgraded CervoMed from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.63.

CervoMed Price Performance

Shares of CRVO opened at $8.78 on Friday. CervoMed has a 12 month low of $1.80 and a 12 month high of $24.40. The stock’s 50-day moving average is $9.28 and its two-hundred day moving average is $6.34. The stock has a market cap of $76.41 million, a PE ratio of -4.03 and a beta of -0.23.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, May 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The firm had revenue of $1.92 million during the quarter, compared to the consensus estimate of $1.70 million.

Institutional Investors Weigh In On CervoMed

A number of institutional investors have recently made changes to their positions in CRVO. Virtu Financial LLC acquired a new position in CervoMed in the fourth quarter worth $26,000. DRW Securities LLC bought a new position in shares of CervoMed in the 4th quarter worth about $30,000. Mariner LLC acquired a new position in shares of CervoMed in the 4th quarter valued at about $30,000. BNP Paribas Financial Markets bought a new stake in shares of CervoMed during the 4th quarter valued at about $32,000. Finally, JPMorgan Chase & Co. raised its stake in CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after acquiring an additional 10,352 shares during the period. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.